Bile Duct Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019


#97820

69pages

GlobalData

$ 3995

In Stock


GlobalData, the industry analysis specialist, has released its new report, Bile Duct Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Bile Duct Cancer Therapeutics market. The report identifies the key trends shaping and driving the global Bile Duct Cancer Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Bile Duct Cancer Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Bile Duct Cancer Therapeutics market. Its scope includes -
  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Bile Duct Cancer Therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018. 
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
  • Analysis of the current and future competition in the seven key countries Bile Duct Cancer Therapeutics market. 
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Bile Duct Cancer Therapeutics market.
  • Analysis of key recent licensing and partnership agreements in Bile Duct Cancer Therapeutics market

Reasons to buy


The report will enhance your decision making capability. It will allow you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. 
  • Develop business strategies by understanding the trends shaping and driving the global Bile Duct Cancer Therapeutics market. 
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Bile Duct Cancer Therapeutics market in future. 
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 
  • Whats the next big thing in the global Bile Duct Cancer Therapeutics market landscape? Identify, understand and capitalize.
Table of Contents

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6

2 Bile Duct Cancer Therapeutics - Introduction 7
2.1 Overview 7
2.2 Classification of Bile Duct Cancer 8
2.3 Epidemiology 9
2.4 Etiology 10
2.5 Pathophysiology 10
2.6 Signs and Symptoms 10
2.7 Diagnosis 11
2.7.1 Physical Exam and History 11
2.7.2 Blood Tests 11
2.7.3 Diagnostic Imaging Techniques 11
2.7.4 Other tests 14
2.8 Staging 14
2.8.1 TNM Classification 14
2.9 Treatment 17
2.9.1 Surgery 17
2.9.2 Chemotherapy 17
2.9.3 Radiation Therapy (RT) 17
2.10 Chemotherapy Regimens 18
2.11 GlobalData Pipeline Report Guidance 19

3 Bile Duct Cancer Therapeutics - Market Characterization 20
3.1 Bile Duct Cancer Therapeutics Market Size (2006-2011) Global 20
3.2 Bile Duct Cancer Therapeutics Market Forecast (2011-2019) Global 22
3.3 Bile Duct Cancer Therapeutics Market Size (2006-2011) US 24
3.4 Bile Duct Cancer Therapeutics Market Forecast (2011-2019) The US 25
3.5 Bile Duct Cancer Therapeutics Market Size (2006-2011) The UK 26
3.6 Bile Duct Cancer Therapeutics Market Forecast (2011-2019) The UK 27
3.7 Bile Duct Cancer Therapeutics Market Size (2006-2011) France 28
3.8 Bile Duct Cancer Therapeutics Market Forecast (2011-2019) France 29
3.9 Bile Duct Cancer Therapeutics Market Size (2006-2011) Germany 30
3.10 Bile Duct Cancer Therapeutics Market Forecast (2011-2019) Germany 31
3.11 Bile Duct Cancer Therapeutics Market Size (2006-2011) Italy 32
3.12 Bile Duct Cancer Therapeutics Market Forecast (2011-2019) Italy 33
3.13 Bile Duct Cancer Therapeutics Market Size (2006-2011) Spain 34
3.14 Bile Duct Cancer Therapeutics Market Forecast (2011-2019) Spain 35
3.15 Bile Duct Cancer Therapeutics Market Size (2006-2011) Japan 36
3.16 Bile Duct Cancer Therapeutics Market Forecast (2011-2019) Japan 37
3.17 Drivers and Barriers for the Bile Duct Cancer Therapeutics Market 38
3.17.1 Drivers for the Bile Duct Cancer Therapeutics Market 38
3.17.2 Barriers for the Bile Duct Cancer Therapeutics Market 38
3.18 Key Events Impacting the Future Market 39
3.18.1 Opportunity and Unmet Need 40
3.19 Key Takeaway 40

4 Bile Duct Cancer Therapeutics Market - Competitive Assessment 41
4.1 Overview 41
4.1.1 Strategic Competitor Assessment 41
4.2 Profiles of the Commonly Used Products in the Bile Duct Cancer Therapeutics Market 42
4.2.1 Gemcitabine 42
4.2.2 Gemcitabine and Oxaliplatin (GEMOX) 42
4.2.3 Gemcitabine and Cisplatin 42
4.2.4 Gemcitabine and Capecitabine 42
4.3 Key Takeaway 42

5 Bile Duct Cancer Therapeutics Market - Pipeline Assessment 43
5.1 Overview 43
5.2 Strategic Pipeline Assessment 43
5.3 Bile Duct Cancer Pipeline Analysis Pipeline by Clinical Phases of Development 43
5.3.1 Bile Duct Cancer Therapeutics Phase III Pipeline 43
5.3.2 Bile Duct Cancer Therapeutics Phase II Pipeline 44
5.3.3 Bile Duct Cancer Therapeutics Phase I/II Pipeline 44
5.3.4 Bile Duct Cancer Therapeutics Phase I Pipeline 45
5.3.5 Bile Duct Cancer Therapeutics Preclinical Pipeline 45
5.4 Bile Duct Cancer Pipeline by Mechanism of Action 46
5.5 Bile Duct Cancer Technology Trends Analytical Framework 47
5.6 Molecule Profile for Selected Drugs under Clinical Development 48
5.6.1 Caprelsa (vandetanib) 48
5.6.2 OTS102 (elpamotide) 48
5.6.3 S-1 (tegafur, gimeracil and oteracil) 49
5.7 Key Takeaway 49

6 Bile Duct Cancer Therapeutics Clinical Trials Mapping 50
6.1 Clinical Trials by Country (US, EU5 and Japan) 50
6.2 Clinical Trials Mapping by Phase 51
6.3 Clinical Trials Mapping by Trial Status 52
6.4 Overall Sponsors 53
6.5 Prominent Sponsors 54
6.6 Top Companies Participating in Bile Duct Cancer Therapeutics Clinical Trials 55

7 Bile Duct Cancer Therapeutics - Strategic Assessment 56
7.1 Future Market Competition Scenario 56

8 Bile Duct Cancer Therapeutics - Future Players in The Market 57
8.1 Introduction 57
8.2 Company Profiles 58
8.2.1 AstraZeneca PLC 58
8.2.2 Otsuka Pharmaceutical Co. Ltd. (OPC) 59

9 Bile Duct Cancer Therapeutics - Licensing and Partnership Deals 61

10 Bile Duct Cancer Therapeutics - Appendix 62

10.1 Definitions 62
10.2 Acronyms 62
10.3 Methodology 63
10.3.1 Coverage 63
10.3.2 Secondary Research 64
10.3.3 Forecasting 64
10.3.4 Primary Research 66
10.3.5 Expert Panel Validation 67
10.4 Contact Us 67
10.5 Disclaimer 67
10.6 Bibliography 67

Table 1: Survival Rates of Bile Duct Cancer 9
Table 2: Prevalence of Bile Duct Cancer in Major Markets 10
Table 3: Intrahepatic Bile Duct Cancer, TNM Definitions 14
Table 4: Intrahepatic Bile Duct Cancer, Stage Grouping 15
Table 5: Perihilar Bile Duct Cancer, TNM Definitions 15
Table 6: Perihilar Bile Duct Cancer, Stage Grouping 16
Table 7: Distal Bile Duct Cancer, TNM Definitions 16
Table 8: Distal Bile Duct Cancer, Stage Grouping 17
Table 9: Bile Duct Cancer Chemotherapy regimens 18
Table 10: Bile Duct Cancer Therapeutics Market, Global, Revenue ($m), 20062011 20
Table 11: Bile Duct Cancer Therapeutics Market, Global, Forecast ($m), 20112019 22
Table 12: Bile Duct Cancer Therapeutics Market, The US, Revenue ($m), 20062011 24
Table 13: Bile Duct Cancer Therapeutics Market, The US, Revenue ($m), 20112019 25
Table 14: Bile Duct Cancer Therapeutics Market, The UK, Revenue ($m), 20062011 26
Table 15: Bile Duct Cancer Therapeutics Market, The UK, Forecast ($m), 20112019 27
Table 16: Bile Duct Cancer Therapeutics Market, France, Revenue ($m), 20062011 28
Table 17: Bile Duct Cancer Therapeutics Market, France, Forecast ($m), 20112019 29
Table 18: Bile Duct Cancer Therapeutics Market, Germany, Revenue ($m), 20062011 30
Table 19: Bile Duct Cancer Therapeutics Market, Germany, Forecast ($m), 20112019 31
Table 20: Bile Duct Cancer Therapeutics Market, Italy, Revenue ($m), 20062011 32
Table 21: Bile Duct Cancer Therapeutics Market, Italy, Forecast ($m), 20112019 33
Table 22: Bile Duct Cancer Therapeutics Market, Spain, Revenue ($m), 20062011 34
Table 23: Bile Duct Cancer Therapeutics Market, Spain, Forecast ($m), 20112019 35
Table 24: Bile Duct Cancer Therapeutics Market, Japan, Revenue ($m), 20062011 36
Table 25: Bile Duct Cancer Therapeutics Market, Japan, Forecast ($m), 20112019 37
Table 26: Bile Duct Cancer Therapeutics Phase III Pipeline 43
Table 27: Bile Duct Cancer Therapeutics Phase II Pipeline 44
Table 28: Bile Duct Cancer Therapeutics Phase I/II Pipeline 44
Table 29: Bile Duct Cancer Therapeutics Phase I Pipeline 45
Table 30: Bile Duct Cancer Therapeutics Preclinical Pipeline 45
Table 31: Bile Duct Cancer Therapeutics Clinical Trials by Country, 2011 50
Table 32: Bile Duct Cancer Therapeutics Clinical Trials by Phase, 2011 51
Table 33: Bile Duct Cancer Therapeutics Clinical Trials by Status, 2011 52
Table 34: Bile Duct Cancer Therapeutics - Clinical Trials by Overall Sponsors, 2011 53
Table 35: Bile Duct Cancer Therapeutics Clinical Trials by Prominent Sponsors, 2011 54
Table 36: Bile Duct Cancer Therapeutics Clinical Trial - Company Sponsors by Phase, 2011 55
Table 37: AstraZeneca Bile Duct Cancer Pipeline 59
Table 38: Otsuka Pharmaceutical Co. Ltd Bile Duct Cancer Pipeline 60
Table 39: OA Therapeutics: Licensing and Partnership Deals 61
Figure 1: Anatomy of the Bile Duct 7
Figure 2: Classification of Bile Duct Cancer 8
Figure 3: Anatomy of the Intrahepatic and Extrahepatic Bile Duct 9
Figure 4: Endoscopic Retrograde Cholangiopancreatography (ERCP) 12
Figure 5: Percutaneous Transhepatic Cholangiography (PTC) 13
Figure 6: Bile Duct Cancer Therapeutics Market, Global, Revenue ($m), 20062011 20
Figure 7: Bile Duct Cancer Therapeutics, Market Share ($m), 2011 21
Figure 8: Bile Duct Cancer Therapeutics Market, Global, Forecast ($m), 20112019 22
Figure 9: Bile Duct Cancer Therapeutics, Market Share ($m), 2019 23
Figure 10: Bile Duct Cancer Therapeutics Market, The US, Revenue ($m), 20062011 24
Figure 11: Bile Duct Cancer Therapeutics Market, The US, Forecast ($m), 20112019 25
Figure 12: Bile Duct Cancer Therapeutics Market, The UK, Revenue ($m), 20062011 26
Figure 13: Bile Duct Cancer Therapeutics, The UK, Forecast ($m), 20112019 27
Figure 14: Bile Duct Cancer Therapeutics Market, France, Revenue ($m), 20062011 28
Figure 15: Bile Duct Cancer Therapeutics Market, France, Forecast ($m), 2011-2019 29
Figure 16: Bile Duct Cancer Therapeutics Market, Germany, Revenue ($m), 20062011 30
Figure 17: Bile Duct Cancer Therapeutics Market, Germany, Forecast ($m), 2011-2019 31
Figure 18: Bile Duct Cancer Therapeutics Market, Italy, Revenue ($m), 20062011 32
Figure 19: Bile Duct Cancer Therapeutics Market, Italy, Forecast ($m), 20112019 33
Figure 20: Bile Duct Cancer Therapeutics Market, Spain, Revenue ($m), 20062011 34
Figure 21: Bile Duct Cancer Therapeutics Market, Spain, Forecast ($m), 20112019 35
Figure 22: Bile Duct Cancer Therapeutics Market, Japan, Revenue ($m), 20062011 36
Figure 23: Bile Duct Cancer Therapeutics Market, Japan, Forecast ($m), 20112019 37
Figure 24: Bile Duct Cancer Therapeutics, Key Events Impacting the Future Market, 2011 39
Figure 25: Opportunity and Unmet Need in the Bile Duct Cancer Therapeutics Market, 2011 40
Figure 26: Bile Duct Cancer Therapeutics Market Strategic Competitor Assessment, 2011 41
Figure 27: Bile Duct Cancer Therapeutics - Pipeline by Phase of Clinical Development, 2011 43
Figure 28: Bile Duct Cancer Therapeutics Clinical Pipeline by Mechanism Of Action, 2011 46
Figure 29: Bile Duct Cancer Therapeutics - Technology Trends Analytical Framework, 2011 47
Figure 30: Bile Duct Cancer Therapeutics - Technology Trends Analytical Framework Description, 2011 47
Figure 31: Bile Duct Cancer Therapeutics Clinical Trials by Country, 2011 50
Figure 32: Bile Duct Cancer Therapeutics Clinical Trials by Phase, 2011 51
Figure 33: Bile Duct Cancer Therapeutics Clinical Trials by Status, 2011 52
Figure 34: Bile Duct Cancer Therapeutics Clinical Trials by Overall Sponsors, 2011 53
Figure 35: Bile Duct Cancer Therapeutics Clinical Trials by Prominent Sponsors, 2011 54
Figure 36: Bile Duct Cancer Therapeutics Clinical Trial - Company Sponsors by Phase, 2011 55
Figure 37: Bile Duct Cancer Therapeutics, Strategic Assessment, 2011 56
Figure 38: Bile Duct Cancer Therapeutics Market Clinical Pipeline by Company, 2011 57
Figure 39: GlobalData Market Forecasting Model 66